Metabolite common among cancers

Feb 08, 2010

A study published online on February 8 in the Journal of Experimental Medicine reports that several distinct mutations found in a subset of patients with acute myelogenous leukemia (AML) result in excess production of the same metabolite.

The enzyme isocitrate dehydrogenase 1 (IDH1), which normally facilitates production of the metabolite {alpha}-ketoglutarate, is mutated in approximately 80% of secondary . This mutant version of IDH1 promotes excess production of a different metabolite: R (-)-2-hydroxyglutarate (2-HG).

A team led by Tak Mak (Toronto) detected elevated concentrations of 2-HG in the serum of the approximately 8% of AML patients with mutations in IDH1. In addition, they identified a mutation in IDH2—the sister enzyme of IDH1—in some AML patients. These patients also had unusually high serum levels of 2-HG.

Additional work is needed to understand if and how 2-HG influences and/or progression. However, as these mutations have so far only been found in cancer, they may prove useful as drug targets.

Explore further: Exercise boosts tumor-fighting ability of chemotherapy, research finds

More information: Gross, S., et al. 2010. J. Exp. Med. doi:10.1084/jem.20092506

add to favorites email to friend print save as pdf

Related Stories

Gene mutation improves leukemia drug's effect

Jun 17, 2008

Gene mutations that make cells cancerous can sometimes also make them more sensitive to chemotherapy. A new study led by cancer researchers at Ohio State University shows that a mutation present in some cases of acute leukemia ...

Recommended for you

User comments : 0